Postconditioning improves postischemic cardiac dysfunction independently of norepinephrine overflow after reperfusion in rat hearts: Comparison with preconditioning

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 1, 2010, Pages 6-13

  Tawa, Masashi ^a,b   Fukumoto, Taiki ^a   Yamashita, Naoto ^a   Ohkita, Mamoru ^a   Ayajiki, Kazuhide ^b   Okamura, Tomio ^b   Matsumura, Yasuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Cardiac sympathetic nerve; Ischemia reperfusion; Nitric oxide; Norepinephrine; Postconditioning; Preconditioning

Indexed keywords

N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION;

ANIMALS; ISCHEMIC PRECONDITIONING; MALE; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE; NITROARGININE; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 75749100626     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181bfb1c1     Document Type: Article

References (42)

1. Follette DM, Fey K, Buckberg GD, et al. Reducing postischemic damage by temporary modification of reperfusate calcium, potassium, pH, and osmolarity. J Thorac Cardiovasc Surg. 1981;82:221-238.
2. Hearse DJ, Bolli R. Reperfusion induced injury: manifestations, mechanisms, and clinical relevance. Cardiovasc Res. 1992:26;101-108.
3. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg. 1999;68:1905-1912.
4. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74:1124-1136.
5. Dirnagl U, Simon RP, Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26:248-254.
6. Yamasowa H, Shimizu S, Inoue T, et al. Endothelial nitric oxide contributes to the renal protective effects of ischemic preconditioning. J Pharmacol Exp Ther. 2005;312:153-159.
7. Jaeschke H. Molecular mechanisms of hepatic ischemia-reperfusion injury and preconditioning. Am J Physiol. 2003;284:G15-G26. (Pubitemid 36076246)
8. Caparrelli DJ, Cattaneo SM 2nd, Bethea BT, et al. Pharmacological preconditioning ameliorates neurological injury in a model of spinal cord ischemia. Ann Thorac Surg. 2002;74:838-844.
9. Cave AC, Hearse DJ. Ischaemic preconditioning and contractile function: studies with normothermic and hypothermic global ischaemia. J Mol Cell Cardiol. 1992;24:1113-1123.
10. Vegh A, Komori S, Szekeres L, et al. Antiarrhythmic effects of preconditioning in anaesthetised dogs and rats. Cardiovasc Res. 1992;26: 487-495.
11. Liu GS, Thomton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit hearts. Circulation. 1991;84:350-356.
12. Goto M, Liu YG, Yang XM, et al. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-621.
13. Schultz JE, Hsu AK, Gross GJ. Ischemic preconditioning in the intact rat heart is mediated by delta1- but not mu- or kappa-opioid receptors. Circulation. 1998;97:1282-1289.
14. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
15. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol. 2003;285:H579-H588.
16. Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion injury. Cardiovasc Res. 2006;70:200-211.
17. Hausenloy DJ, Yellon DM. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res. 2006;70:240-253.
18. Tong H, Chen W, Steenbergen C, et al. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000;87:309-315.
19. Schömig A, Haass M, Richardt G. Catecholamine release and arrhythmias in acute myocardial ischemia. Eur Heart J. 1991;12(Suppl F):38-47.
20. Imamura M, Lander HM, Levi R. Activation of histamine H3 receptors inhibits carrier-mediated norepinephrine release during protracted myocardial ischemia: comparison with adenosine A1-receptors and a2-adrenoceptors. Circ Res. 1996;78:475-481.
21. Tawa M, Fukumoto T, Ohkita M, et al. Role of endogenous endothelin-1 in post-ischemic cardiac dysfunction and norepinephrine overflow in rat hearts. Eur J Pharmacol. 2008;591:182-188.
22. Miura T, Kawamura S, Tatsuno H, et al. Ischemic preconditioning attenuates cardiac sympathetic nerve injury via ATP-sensitive potassium channels during myocardial ischemia. Circulation. 2001;104:1053-1058.
23. Seyfarth M, Richardt G, Mizsnyak A, et al. Transient ischemia reduces norepinephrine release during sustained ischemia: neural preconditioning in isolated rat heart. Circ Res. 1996;78:573-580.
24. Kloner RA, Dow J, Bhandari A. Postconditioning markedly attenuates ventricular arrhythmia after ischemia-reperfusion. J Cardiovasc Pharmacol Ther. 2006;11:55-63.
25. Grunt M, Glaser J, Schmidhuber H, et al. Effects of corticotrophinreleasing factor on isolated rat heart activity. Am J Physiol. 1993;264: H1124-H1129.
26. Sasaoka T, Egi Y, Tawa M, et al. Angiotensin II type 2 receptor-mediated inhibition of norepinephrine release in isolated rat hearts. J Cardiovasc Pharmacol. 2008;52:176-183.
27. Sato H, Jordan JE, Zhao ZQ, et al. Gradual reperfusion reduces infarct size and endothelial injury but augments neutrophil accumulation. Ann Thorac Surg. 1997;64:1099-1107.
28. Takeo S, Liu JX, Tanonaka K, et al. Reperfusion at reduced flow rates enhances postischemic contractile recovery of perfused heart. Am J Physiol. 1995;268:H2384-H2395.
29. Arora RC, Armour JA. Adenosine A1 receptor activation reduces myocardial reperfusion effects on intrinsic cardiac nervous system. Am J Physiol. 2003;284:R1314-R1321.
30. Foreman RD, Linderoth B, Ardell JL, et al. Modulation of intrinsic cardiac neurons by spinal cord stimulation: implications for its therapeutic use in angina pectoris. Cardiovasc Res. 2000;47:367-375.
31. Fujii T, Kurata H, Takaoka M, et al. The role of renal sympathetic nervous system in the pathogenesis of ischemic acute renal failure. Eur J Pharmacol. 2003;481:241-248.
32. Cargnoni A, Ceconi C, Curello S, et al. Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia. Mol Cell Biochem. 1996;160-161:187-194.
33. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest. 1999;104:1223-1233.
34. Remme CA, Schumacher CA, de Jong JW, et al. K(ATP) channel opening during ischemia: effects on myocardial noradrenaline release and ventricular arrhythmias. J Cardiovasc Pharmacol. 2001;38:406-416.
35. Peart J, Headrick JP. Adenosine-mediated early preconditioning in mouse: protective signaling and concentration dependent effects. Cardiovasc Res. 2003;58:589-601.
36. du Toit EF, Genis A, Opie LH, et al. A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154:41-50.
37. Louhelainen M, Vahtola E, Kaheinen P, et al. Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/ Rapp rats. Br J Pharmacol. 2007;150:851-861.
38. Zangrillo A, Biondi-Zoccai G, Mizzi A, et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth. 2009;23:474-478.
39. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth. 2009;102:198-204.
40. Martorana PA, Kettenbach B, Bohn H, et al. Antiischemic effects of pirsidomine, a new nitric oxide donor. Eur J Pharmacol. 1994;257:267-273.
41. Zhang JM, Orihashi K, Sueda T, et al. Cardioprotective effects of FK409, a nitric oxide donor, after isolated rat heart preservation for 16 hours. Ann Thorac Surg. 2000;70:1601-1606.
42. Pabla R, Buda AJ, Flynn DM, et al. Intracoronary nitric oxide improves postischemic coronary blood flow and myocardial contractile function. Am J Physiol. 1995;269:H1113-H1121.